ArticleScientific reports2025
Mitochondrial proteins contribute to the pathogenesis of myasthenia gravis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Myasthenia gravis (MG) is an autoimmune disorder mediated by B-cells, characterized by muscle weakness and fatigue. Mitochondria, essential for energy production and muscle function, have been implicated in MG. Despite their importance, the exact relationship between mitochondrial proteins (MPs) and MG remains unclear. This study utilized two-sample Mendelian Randomization (TSMR) to investigate potential causal associations between MPs and MG. Data from the largest available genome-wide associated study (GWAS), comprising 1873 acetylcholine receptor (AchR) antibody-positive MG patients (1278 late-onset MG [LOMG] and 595 early-onset MG [EOMG]), were analyzed. A total of 66 MPs were selected as exposure variables, with MG and its subtypes as outcomes. Analyses employed inverse variance weighted (IVW), MR-PRESSO, MR-Egger, and weighted median methods, with heterogeneity assessed using Cochran's Q statistic. Significant causal associations were found between MPs and MG subtypes. For LOMG, GrpE protein homolog 1, oligoribonuclease, protein SCO1 homolog, and rRNA methyltransferase 3 were linked to increased risk. Cytochrome c oxidase subunit 7A1 was associated with higher EOMG risk, while [pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, dihydrolipoyl dehydrogenase, and NFU1 iron-sulfur cluster scaffold were linked to reduced EOMG risk. MPs such as dihydrolipoyl dehydrogenase and NAD-dependent protein deacylase sirtuin-5 showed protective effects against MG, while GrpE protein homolog 1, mitochondrial glutamate carrier 2, oligoribonuclease, and protein SCO1 homolog were associated with increased risk. This MR analysis suggests potential causal relationships between MPs and MG, highlighting the need for further research to validate these findings and explore the mechanisms underlying these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.